MedImmune strives to provide better medicines to patients, new medical options for physicians, and rewarding careers to employees. Dedicated to advancing science and medicine to help people live better lives, the company is focused on infection, oncology, respiratory disease and inflammation, cardiovascular/gastrointestinal disease and neuroscience. The company has two marketed products and an advancing pipeline of promising candidates, all designed to treat or prevent a number of debilitating or life-threatening diseases.

MedImmune's state-of-the-art R&D facility and worldwide corporate headquarters is located in Gaithersburg, Maryland.

With approximately 3,000 employees worldwide, MedImmune is headquartered in Maryland with facilities in Pennsylvania, California, Kentucky, the United Kingdom and the Netherlands.

The company's currently marketed products include Synagis^® (palivizumab), and FluMist^® (Influenza Virus Vaccine Live, Intranasal), with additional products in clinical testing.